t(11;14)

MCL Researchers

63 clinicians and researchers advancing the field of mantle cell lymphoma.

Ahmed Sawas

Instructor in Medicine · New York Cancer & Blood Specialists / Columbia University

New York, United States

Novel therapiesPrognostic biomarkersB-cell lymphoma
Alex Herrera

Chief, Division of Lymphoma · City of Hope Comprehensive Cancer Center

Duarte, United States

ImmunotherapyCAR-T therapyTransplantClinical trials
Andre Goy

Chairman and Executive Director, John Theurer Cancer Center · Hackensack Meridian Health

Hackensack, United States

Novel agentsLenalidomideClinical trials
Anita Kumar

Associate Attending · Memorial Sloan Kettering Cancer Center

New York, United States

Frontline therapyMRD-guided therapyClinical trials
Bijal Shah

Associate Member · Moffitt Cancer Center

Tampa, United States

CAR-T therapyRelapsed/refractory MCLNovel agents
Birgitta Sander

Professor Emeritus of Pathology · Department of Laboratory Medicine, Karolinska Institutet

Stockholm, Sweden

MCL pathologyMolecular diagnosticsSOX11Biomarkers
Brad Kahl

Professor of Medicine, Director of Lymphoma Program · Washington University School of Medicine

St. Louis, United States

Frontline therapyClinical trialsIndolent lymphoma
Brian Hill

Director, Lymphoid Malignancies Program · Cleveland Clinic

Cleveland, United States

Novel agentsClinical trialsTransplant
Catherine Thieblemont

Professor of Hematology, Head of Hemato-Oncology · Hopital Saint-Louis, Universite Paris Cite

Paris, France

Novel agentsClinical trialsElderly MCLReal-world evidence
Chan Yoon Cheah

Professor, Consultant Haematologist · Sir Charles Gairdner Hospital / University of Western Australia

Perth, Australia

BTK inhibitorsNovel agentsClinical trialsCNS lymphoma
Christian Buske

Professor, Director of Institute for Experimental Cancer Research · University Hospital Ulm

Ulm, Germany

Clinical trialsElderly MCLEuropean MCL Network
Clementine Sarkozy

Hematologist · Institut Curie, Department of Hematology

Saint-Cloud, France

Clinical trialsNovel agentsRelapsed/refractory MCLLYSA
Constantine Tam

Professor, Director of Haematology · Peter MacCallum Cancer Centre / St Vincent's Hospital / University of Melbourne

Melbourne, Australia

Ibrutinib-venetoclax combinationTP53-mutated MCLTime-limited therapyCAR-T bridging
Dok Hyun Yoon

Professor of Oncology, Director of CAR-T Therapy Center · Asan Medical Center / University of Ulsan

Seoul, South Korea

Clinical trialsNovel agentsRelapsed/refractory MCL
Elias Campo

Professor of Pathology · Hospital Clinic de Barcelona / University of Barcelona

Barcelona, Spain

MCL pathologyWHO classificationMolecular diagnosticsCCND1
Eva Gine

Senior Consultant Hematologist · Hospital Clinic de Barcelona / IDIBAPS / CIBERONC

Barcelona, Spain

Clinical trialsFrontline therapyElderly MCL
Eva Kimby

Professor Emerita of Hematology · Karolinska Institutet

Stockholm, Sweden

Nordic MCL protocolsElderly MCLPrognostic biomarkers
Franck Morschhauser

Professor of Hematology, President of LYSA · CHU de Lille / University of Lille

Lille, France

BispecificsNovel agentsClinical trialsLYSA leadership
Frederick Locke

Department Chair, Blood and Marrow Transplant and Cellular Immunotherapy · Moffitt Cancer Center

Tampa, United States

CAR-T therapyCell therapyTransplant
Georg Lenz

Professor of Translational Oncology, Director of Hematology/Oncology · University Hospital Munster

Munster, Germany

MCL genomicsLymphoma biologyNovel agents
German Ott

Professor of Pathology, Head of Department of Clinical Pathology · Robert-Bosch-Krankenhaus

Stuttgart, Germany

MCL pathologyBlastoid MCLMorphologyBiomarkers
Grzegorz Nowakowski

Professor of Oncology and Medicine · Mayo Clinic

Rochester, United States

Novel agentsBispecificsClinical trials
Hanneke Kluin-Nelemans

Professor Emerita of Hematology · University Medical Center Groningen

Groningen, Netherlands

Elderly MCLEuropean MCL NetworkFrontline therapy
Jia Ruan

Professor of Clinical Medicine · Weill Cornell Medicine

New York, United States

Novel agentsLenalidomideFrontline therapy
John Leonard

Richard T. Silver Distinguished Professor of Hematology and Medical Oncology · Weill Cornell Medicine

New York, United States

Lenalidomide-rituximabChemo-free approachesPrecision medicine
John Pagel

Chief of Hematologic Malignancies, Director of Stem Cell Transplantation · Swedish Cancer Institute

Seattle, United States

Novel agentsRadioimmunotherapyClinical trials
Jonathon Cohen

Professor, Co-Director of Lymphoma Program · Emory University / Winship Cancer Institute

Atlanta, United States

Novel agentsClinical trialsRelapsed/refractory MCL
Jorge Romaguera

Professor, Department of Lymphoma and Myeloma · MD Anderson Cancer Center

Houston, United States

Frontline therapyHyper-CVADIntensive chemotherapy
Kami Maddocks

Professor of Hematology, Lymphoma Program Director · Ohio State University

Columbus, United States

Novel agentsBTK inhibitorsClinical trials
Koji Izutsu

Director, Department of Hematology · National Cancer Center Hospital

Tokyo, Japan

Clinical trialsGuidelinesNovel agents
Krish Patel

Director of Lymphoma Research · Sarah Cannon Research Institute

Nashville, United States

BTK inhibitorsNovel agentsClinical trials
Leticia Quintanilla-Martinez

Professor of Pathology · University of Tubingen

Tubingen, Germany

MCL pathologyMolecular pathologyDiagnostics
Lori Leslie

Associate Professor, Director of Indolent Lymphoma and CLL Research · Hackensack Meridian Health

Hackensack, United States

Novel agentsClinical trialsRelapsed/refractory MCL
Manali Kamdar

Associate Professor, Clinical Director of Lymphoma Services · University of Colorado

Aurora, United States

Novel agentsCAR-T therapyClinical trials
Marco Ladetto

Associate Professor of Hematology, President of FIL · University of Eastern Piedmont / Azienda Ospedaliera SS Antonio e Biagio

Alessandria, Italy

MRD monitoringFrontline therapyTransplant
Martin Dreyling

Professor of Medicine · Department of Medicine III, LMU University Hospital

Munich, Germany

Clinical trialsEuropean MCL NetworkFrontline therapyGuidelines
Mats Jerkeman

Professor of Clinical Oncology · Lund University / Skane University Hospital

Lund, Sweden

Clinical trialsNordic MCL studiesFrontline therapyIbrutinib
Michael Wang

Professor, Department of Lymphoma and Myeloma; Director, MCL Program of Excellence · MD Anderson Cancer Center

Houston, United States

BTK inhibitorsClinical trialsNovel agentsRelapsed/refractory MCL
Michael Williams

Byrd S. Leavell Professor of Medicine · University of Virginia

Charlottesville, United States

MCL biologyGenomicsMinimal residual disease
Mitchell Smith

Professor of Medicine, Director of Cancer and Blood Disorders Division · GW Cancer Center, George Washington University

Washington, United States

Targeted therapiesImmunotherapyCAR-T therapy
Nathan Fowler

Professor of Medicine · MD Anderson Cancer Center

Houston, United States

Novel agentsFrontline therapyIndolent lymphoma
Olivier Hermine

Professor of Hematology · Hopital Necker / Universite Paris Cite

Paris, France

MCL biologyClinical trialsFrontline therapy
Peter Martin

Professor of Medicine, Chief of Lymphoma Program · Weill Cornell Medicine

New York, United States

BTK inhibitorsFrontline therapyClinical trials
Pier Luigi Zinzani

Professor of Hematology · University of Bologna / Policlinico S. Orsola-Malpighi

Bologna, Italy

Novel agentsRelapsed/refractory MCLPI3K inhibitorsGuidelines
Pierre Morel

Hematologist · CHU Amiens-Picardie

Amiens, France

Frontline therapyElderly MCLLYSA
Preetesh Jain

Assistant Professor, Department of Lymphoma and Myeloma · MD Anderson Cancer Center

Houston, United States

BTK inhibitorsBispecificsRelapsed/refractory MCLTP53-mutated MCL
Roch Houot

Professor of Hematology · CHU de Rennes

Rennes, France

CAR-T therapyImmunotherapyCell therapy
Samir Parekh

Professor of Medicine · Icahn School of Medicine at Mount Sinai

New York, United States

MCL genomicsEpigeneticsTranslational research
Selina Chen-Kiang

Professor of Pathology and Laboratory Medicine · Weill Cornell Medicine

New York, United States

Cell cycle biologyCDK4/6MCL biology
Simon Rule

Professor of Hematology · University of Plymouth / Derriford Hospital

Plymouth, United Kingdom

BTK inhibitorsNovel agentsRelapsed/refractory MCL
Stephen Ansell

Professor of Medicine, Chair of Division of Hematology · Mayo Clinic

Rochester, United States

Tumor microenvironmentImmunotherapyNovel agents
Steven Le Gouill

Director of Hospital Group and Professor of Hematology · Institut Curie / Paris-Saclay University

Paris, France

MRD-guided therapyFrontline therapyTransplantClinical trials
Thierry Lamy

Professor of Hematology, Head of Hematology Department · CHU de Rennes

Rennes, France

Clinical trialsLYSAFrontline therapy
Thomas Witzig

Professor of Medicine · Mayo Clinic

Rochester, United States

PI3K inhibitorsDNA damage responseNovel agents
Timothy Fenske

Professor of Medicine, Section Head of Hematologic Malignancies · Medical College of Wisconsin

Milwaukee, United States

TransplantCAR-T therapyClinical trials
Toby Eyre

Consultant Haematologist · University of Oxford / Oxford University Hospitals

Oxford, United Kingdom

Real-world evidenceBTK inhibitorsNovel agentsTP53-mutated MCL
Tycel Phillips

Associate Professor · City of Hope

Duarte, United States

Novel agentsCAR-T therapyRelapsed/refractory MCL
Vincent Ribrag

Senior Hematologist · Gustave Roussy / Universite Paris-Saclay

Villejuif, France

Novel agentsEZH2 inhibitorsClinical trials
Vu Nguyen Ngo

Associate Professor, Department of Systems Biology · Beckman Research Institute, City of Hope

Duarte, United States

Cyclin D1 mutationsIbrutinib resistanceB-cell receptor signalingMCL pathogenesis
Wojciech Jurczak

Professor, Head of Clinical Oncology Department · Maria Sklodowska-Curie National Research Institute of Oncology

Krakow, Poland

BTK inhibitorsVenetoclax combinationsTP53-mutated MCL
Wolfram Klapper

Professor of Pathology · University Hospital Schleswig-Holstein

Kiel, Germany

MCL pathologyKi-67DiagnosticsBiomarkers
Won Seog Kim

Professor, Head of Malignant Lymphoma Center · Samsung Medical Center / Sungkyunkwan University

Seoul, South Korea

Clinical trialsNovel agentsAsian MCL data
Yucai Wang

Associate Professor of Medicine and Oncology · Mayo Clinic

Rochester, United States

BTK inhibitorsNovel agentsReal-world evidence